Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donanemab in early cognitive decline with Lewy body features and confirmed alpha-synuclein and amyloid co-pathology
jRCT2051260098Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised trial in dementia with Lewy bodies (DLB) and confusion comparing Donanemab (LY3002813) with Placebo (2 arms). Primary endpoint: Change from baseline in Clinical Dementia Rating - Sum of Boxes. Started Aug 2026; status: recruiting.
02
Drugs
donanemab
03
Conditions
dementia with Lewy bodies (DLB)confusion
Beyond the preview
Go deeper on jRCT2051260098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260098.